Pulmonary Fibrosis Awareness Month may be coming to a close, but it's important to keep the momentum going, columnist Sam Kirton says.
Interstitial Lung Disease (ILD) is a chronic condition marked by lung inflammation and scarring that makes breathing ...
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...
September is Pulmonary Fibrosis Awareness Month. Pulmonary fibrosis is a disease marked by scarring in the lungs.
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
A University of Colorado professor won the 2024 Alton Ochsner Award for his work on disease risk factors for idiopathic ...
Aileron Therapeutics completes patient enrollment in Cohort 2 of phase 1b trial of LTI-03 in idiopathic pulmonary fibrosis: Austin, Texas Wednesday, September 25, 2024, 15:00 Hrs ...
A new statistical technique developed by a researcher at the Texas A&M University School of Public Health and colleagues ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback